Cutler Group’s Opus Genetics IRD Stock Holding History

Cutler Group’s Portfolio IRD Stock Details IRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3,800	Closed	-$1K	–	6261
2021 Q3	$1K	Hold	3,800	–	–	﹤0.01%	5507
2021 Q2	$6K	Buy	+3,800	New	+$18.9K	﹤0.01%	4358

Other funds holding IRD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return

Cutler Group's IRD Position: Q3 2022 in Review

Cutler Group sold out of Opus Genetics (IRD) in Q3 2022, closing a stake of 200 shares.

Cutler Group first reported a position in IRD in Q2 2021 and held it in 4 quarters. The position peaked at $41K in Q2 2021. 37 funds tracked by Wall St. Rank hold IRD as of Q3 2022.

Cutler Group reported no remaining Opus Genetics position as of Q3 2022 after selling out during the quarter.
Cutler Group sold 200 Opus Genetics shares in Q3 2022.
Cutler Group first reported a position in Opus Genetics in Q2 2021 and held it in 4 quarters.
Cutler Group's Opus Genetics position peaked at $41K in Q2 2021.
37 funds tracked by Wall St. Rank held Opus Genetics as of Q3 2022.

Based on Cutler Group's 13F filing for Q3 2022, filed 25 Oct 2022.